ZNTL - Pfizer Zentalis plan to start phase 1/2 trial of ZN-c3 for colorectal cancer

• Zentalis Pharmaceuticals ( NASDAQ: ZNTL ) on Monday said it plans to start the first study under its collaboration with Pfizer ( NYSE: PFE ) for its cancer drug candidate ZN-c3.
• The study is one part of an agreement between the companies, which was previously announced along with the New York-based pharma giant's $25M equity investment in Zentalis.
• The companies will start a phase 1/2 dose escalation study of ZN-c3 in combination with encorafenib (sold as Braftovi by Pfizer), and cetuximab (marketed as Erbitux by Eli Lilly) — known as BEACON regimen — to treat patients with BRAF V600E-mutated metastatic colorectal cancer (mCRC).
• Zentalis expects to start patient enrollment in Q1 2023.
• ZNTL +3% to $23 premarket Oct. 24

For further details see: